BACKGROUND: Research in the treatment of Crohn's disease (CD) supports anti-inflammatory benefits of n-3 fatty acids from fish oil, prebiotics, and antioxidants. A nutritionally balanced inflammatory bowel disease nutrition formula (IBDNF) enriched with these compounds has the potential to improve nutrition status and disease activity in CD. METHODS: This is an open-label pilot study investigating the effects of IBDNF on nutrition status in CD patients. Twenty-eight patients with active CD on stable medication were asked to consume 16 oz of IBDNF/d for 4 months. Nutrition status was assessed with dual-energy X-ray absorptiometry scans and serum micronutrient levels. Disease activity and quality of life were measured using the Crohn's Disease Activity Index (CDAI) and the Inflammatory Bowel Disease Questionnaire (IBDQ). RESULTS: Twenty patients completed the final visit. After 4 months, there was a significant decrease in plasma phospholipid levels of arachidonic acid with increases in eicosapentaenoic acid (EPA) and docosahexaenoic acid. Ten patients had a final EPA concentration of >2%. There was improvement in fat-free and fat mass in patients with final EPA >2% (P = .014 and P = .05). Vitamin D (25-OH) levels improved in all patients (18.5-25.9 ng/mL, P < .001). Those with EPA >2% had significantly lower CDAI (116 ± 94.5 vs 261.8 ± 86.5; P = .005) and higher IBDQ (179.1 ± 26.6 vs 114.6 ± 35.9, P < .001) compared to those with EPA <2%. CONCLUSIONS: IBDNF has the potential to deposit fat-free and fat mass, improve vitamin D status, and improve quality of life in CD patients.
BACKGROUND: Research in the treatment of Crohn's disease (CD) supports anti-inflammatory benefits of n-3 fatty acids from fish oil, prebiotics, and antioxidants. A nutritionally balanced inflammatory bowel disease nutrition formula (IBDNF) enriched with these compounds has the potential to improve nutrition status and disease activity in CD. METHODS: This is an open-label pilot study investigating the effects of IBDNF on nutrition status in CDpatients. Twenty-eight patients with active CD on stable medication were asked to consume 16 oz of IBDNF/d for 4 months. Nutrition status was assessed with dual-energy X-ray absorptiometry scans and serum micronutrient levels. Disease activity and quality of life were measured using the Crohn's Disease Activity Index (CDAI) and the Inflammatory Bowel Disease Questionnaire (IBDQ). RESULTS: Twenty patients completed the final visit. After 4 months, there was a significant decrease in plasma phospholipid levels of arachidonic acid with increases in eicosapentaenoic acid (EPA) and docosahexaenoic acid. Ten patients had a final EPA concentration of >2%. There was improvement in fat-free and fat mass in patients with final EPA >2% (P = .014 and P = .05). Vitamin D (25-OH) levels improved in all patients (18.5-25.9 ng/mL, P < .001). Those with EPA >2% had significantly lower CDAI (116 ± 94.5 vs 261.8 ± 86.5; P = .005) and higher IBDQ (179.1 ± 26.6 vs 114.6 ± 35.9, P < .001) compared to those with EPA <2%. CONCLUSIONS: IBDNF has the potential to deposit fat-free and fat mass, improve vitamin D status, and improve quality of life in CDpatients.
Authors: Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos Journal: Am J Gastroenterol Date: 2007-10-04 Impact factor: 10.864
Authors: Catarina Sousa Guerreiro; Marília Cravo; Ana Raimundo Costa; Ana Miranda; Lourdes Tavares; Paula Moura-Santos; Pedro MarquesVidal; Carlos Nobre Leitão Journal: Am J Gastroenterol Date: 2006-08-04 Impact factor: 10.864
Authors: Sang Lee; Kathleen M Gura; Sendia Kim; Danielle A Arsenault; Bruce R Bistrian; Mark Puder Journal: Nutr Clin Pract Date: 2006-08 Impact factor: 3.080
Authors: Y S Huang; S Chaudhary; J M Thurmond; E G Bobik; L Yuan; G M Chan; S J Kirchner; P Mukerji; D S Knutzon Journal: Lipids Date: 1999-07 Impact factor: 1.880
Authors: Lars Erik Bartels; Søren Peter Jørgensen; Jørgen Agnholt; Jens Kelsen; Christian Lodberg Hvas; Jens Frederik Dahlerup Journal: Int Immunopharmacol Date: 2007-10-05 Impact factor: 4.932
Authors: Luzia Valentini; Lennart Schaper; Carsten Buning; Susanne Hengstermann; Thomas Koernicke; Wolfgang Tillinger; Francesco William Guglielmi; Kristina Norman; Sabine Buhner; Johann Ockenga; Matthias Pirlich; Herbert Lochs Journal: Nutrition Date: 2008-05-21 Impact factor: 4.008
Authors: Carol S Brotherton; Christopher A Martin; Millie D Long; Michael D Kappelman; Robert S Sandler Journal: Clin Gastroenterol Hepatol Date: 2015-12-31 Impact factor: 11.382
Authors: Jose M Comeche; Pablo Caballero; Ana Gutierrez-Hervas; Sofia García-Sanjuan; Iris Comino; Cesare Altavilla; Jose Tuells Journal: Nutrients Date: 2019-11-04 Impact factor: 5.717